Hexolame
Clinical data | |
---|---|
Other names | 17β-((6-Hydroxyhexyl)amino)estradiol; 17β-[(6-Hydroxyhexyl)amino]estra-1,3,5(10)-trien-3-ol; N-(3-Hydroxy-1,3,5(10)-estratrien 17-yl)-6-hydroxyhexylamine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H37NO2 |
Molar mass | 371.565 g·mol−1 |
3D model (JSmol) | |
| |
|
Hexolame, also known as 17β-((6-hydroxyhexyl)amino)estradiol, is a synthetic, steroidal estrogen and a 17β-aminoestrogen with anticoagulant effects that was first described in 1990 and was never marketed.[1][2][3]
References
[edit]- ^ Negwer M, Scharnow HG (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 12610. ISBN 978-3-527-30247-5.
- ^ Rubio-Póo C, Lemini C, García-Mondragón J, de la Peña A, Jayme V, Mendoza-Patiño N, et al. (February 1990). "The anticoagulant effect of hexolame, N-(3-hydroxy-1,3,5(10)-estratrien-17 beta-yl)-6-hydroxyhexylamine, another amino-estrogen with prolonged anticoagulant effect". Steroids. 55 (2): 83–86. doi:10.1016/0039-128x(90)90030-f. PMID 2326832. S2CID 32937513.
- ^ Rubio-Póo C, Lemini C, Silva G, García-Mondragón J, Zavala E, Castro D, et al. (1993). "Comparison of the time course of anticoagulant and estrogenic effects of prolame, butolame, pentolame and hexolame, a homologous series of 17 beta-amino estrogens". Proceedings of the Western Pharmacology Society. 36: 143–147. PMID 8378368.